IRONMAN adds support for iron repletion in HF

The IRONMAN trial adds further support to the known benefits of intravenous iron therapy in patients with heart failure (HF) with reduced ejection fraction and iron deficiency, but narrowly misses the primary end point of hospitalization for HF and cardiovascular death.

Detalles Bibliográficos
Autor principal: Fernández-Ruiz, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684863/
https://www.ncbi.nlm.nih.gov/pubmed/36414679
http://dx.doi.org/10.1038/s41569-022-00815-5
Descripción
Sumario:The IRONMAN trial adds further support to the known benefits of intravenous iron therapy in patients with heart failure (HF) with reduced ejection fraction and iron deficiency, but narrowly misses the primary end point of hospitalization for HF and cardiovascular death.

Ejemplares similares